Company / PP&E (Net)
Xenon Pharmaceuticals Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$8.7M
FY2025
5-year range
$4.5M / $10.3M
FY2021-FY2025
Trend
-15.1%
vs FY2024
Sector context
#98 of 193
Health Care
What the data says
At $9M, Xenon Pharmaceuticals Inc.'s pp&e (net) ranks #98 of 193 in the Health Care sector. Declined from $10M to $9M over the past 2 years.
Based on SEC 10-K filings.
$9M in FY2025 with a 5-year CAGR of +19.7%.
Declined from $10M to $9M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +10.3%
- 5-Year CAGR
- +19.7%
- 10-Year CAGR
- -
Sector benchmark
#98 of 193 in Health CareTop 51% of 193This company $8.7M Sector average $777.6M
▼
-98.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +19.7%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 15.1% year-over-year.
- Ranks #98 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.51 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.7M | -15.1% |
| FY2024 | $10.3M | +6.5% |
| FY2023 | $9.7M | +48.5% |
| FY2022 | $6.5M | +45.5% |
| FY2021 | $4.5M | +25.7% |
| FY2020 | $3.6M | +114.1% |
| FY2019 | $1.7M | +67.5% |
| FY2018 | $991.0K | -7.4% |
| FY2017 | $1.1M | -23.8% |
| FY2016 | $1.4M | -29.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026